SCHERER HEALTHCARE INC Form 10-Q August 08, 2001

OuickLinks -- Click here to rapidly navigate through this document

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2001

Commission File No. 0-10552

SCHERER HEALTHCARE, INC.

(Exact name of registrant as specified in its Charter)

Delaware

59-0688813

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

120 Interstate North Parkway, S.E., Suite 305, Atlanta, Georgia 30339 (Address of principal executive offices, including Zip Code)

(770) 933-1800

(Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes/x/ No//

Indicate the number of shares of each of the issuer's classes of Common Stock, as of the latest practicable date:

Class
Outstanding as of August 2,
2001

Common Stock, \$0.01 par value
4,323,130

SCHERER HEALTHCARE, INC.

Quarterly Report on Form 10-Q For the Quarter Ended June 30, 2001

Table of Contents

Item Number		Page Number
	PART I. FINANCIAL INFORMATION	
1	Financial Statements:	
	Condensed Consolidated Balance Sheets as of June 30, 2001 and March 31, 2001	3
	Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2001 and 2000	5
	Condensed Consolidated Statements of Cash Flows for the Three Months Ended June 30, 2001 and 2000	6
	Notes to Condensed Consolidated Financial Statements	7
2	Management's Discussion and Analysis of Financial Condition and Results of Operations	9
	PART II. OTHER INFORMATION	
6	Exhibits and Reports on Form 8-K	13
	SIGNATURES	14
	2	

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

	June 30, 2001		Ma	rch 31, 2001
	(Unaudited)		
CURRENT ASSETS				
Cash and cash equivalents	\$	5,562,000	\$	4,398,000
Accounts receivable, less allowance for doubtful accounts of \$333,000 and \$319,000, respectively		4,353,000		4,747,000
Interest receivable		232,000		243,000
Inventories		303,000		333,000
Prepaid and other		286,000		232,000
Total current assets		10,736,000		9,953,000
PROPERTY AND EQUIPMENT		9,515,000		9,287,000
Less accumulated depreciation		(5,007,000)		(4,722,000)

	June 30, 2001	March 31, 2001
Net property and equipment	4,508,000	4,565,000
OTHER ASSETS		
Intangible assets, net	3,559,000	3,538,000
Investments	11,357,000	11,280,000
Deferred income taxes	497,000	761,000
Other	457,000	451,000
Net assets of discontinued operations	475,000	481,000
Total other assets	16,345,000	16,511,000
TOTAL ASSETS	\$ 31,589,000	\$ 31,029,000

See notes to condensed consolidated financial statements.

3

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS' EQUITY

	June 30, 2001		, 2001 March 31, 20	
	(1	Unaudited)		
CURRENT LIABILITIES				
Accounts payable	\$	1,210,000	\$	1,089,000
Accrued expenses		1,005,000		989,000
Unearned revenues		488,000		478,000
Current maturities of long-term debt		271,000		265,000
Income taxes payable		[cad228]		36,000
Total current liabilities		2,974,000		2,857,000
LONG-TERM DEBT, net of current maturities		555,000		551,000
OTHER LIABILITIES		87,000		100,000
COMMITMENTS AND CONTINGENCIES				
STOCKHOLDERS' EQUITY				
Convertible preferred stock \$.01 par value, 2,000,000 shares authorized; 21,535 shares issued and outstanding at June 30, 2001 and				
21.704 at March 31, 2001				
Common stock \$.01 par value, 12,000,000 shares authorized;				
4,714,159 shares issued at June 30, 2001 (4,713,411 at March 31,				
2001); 4,323,130 shares outstanding at June 30, 2001 (4,322,382 at				
March 31, 2001)		47,000		47,000
Capital in excess of par value		22,067,000		22,115,000

	June 30, 2001	March 31, 2001
Retained earnings	8,950,000	8,450,000
Less treasury stock, at cost	(3,091,000)	(3,091,000)
Total stockholders' equity	27,973,000	27,521,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 31,589,000	\$ 31,029,000

See notes to condensed consolidated financial statements.

4

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Three months ended June 30,

	2001		2000		
NET SALES	\$	5,034,000	\$	4,626,000	
			_		
COSTS AND EXPENSES					
Cost of goods sold		3,192,000		2,759,000	
Selling, general and administrative		1,288,000		1,301,000	
Total costs and expenses		4,480,000		4,060,000	
OPERATING INCOME		554,000		566,000	
OTHER INCOME (EXPENSE)					
Interest income		192,000		241,000	
Equity in net income of unconsolidated companies		39,000			
Other income (expense), net		(3,000)		(49,000)	
Total other income, net		228,000		192,000	
INCOME BEFORE INCOME TAXES		782,000		758,000	
PROVISION FOR INCOME TAXES		282,000		29,000	
NET INCOME	\$	500,000	\$	729,000	
Basic net income per common share	\$	0.12	\$	0.17	
Diluted net income per common share	\$	0.11	\$	0.16	
2. Macca nee meetine per common snare	Ψ	0.11	Ψ	0.10	
Weighted average common shares outstanding basic		4,322,615		4,336,383	
Weighted average common shares outstanding diluted		4,524,813		4,548,142	

Three months ended June 30,

See notes to condensed consolidated financial statements.

5

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Three months ended June 30,

	June 30,		
		2001	2000
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net income Adjustments to reconcile net income to net cash provided by operating activities:	\$	500,000 \$	729,000
Depreciation and amortization		331,000	378,000
Deferred taxes		264,000	6,000
Equity in net income of unconsolidated companies		(39,000)	
Other noncash charges and credits, net		14,000	
Changes in operating assets and liabilities:			
Accounts receivable		380,000	93,000
Interest receivable		11,000	(34,000)
Inventories		30,000	37,000
Prepaid and other		(54,000)	43,000
Other assets		(6,000)	
Income taxes, net		(36,000)	9,000
Accounts payable and accrued expenses		137,000	(140,000)
Unearned revenue		10,000	
Net assets of discontinued operations		6,000	(22,000)
Other liabilities		(13,000)	(32,000)
Net cash provided by operating activities		1,535,000	1,067,000
CASH FLOWS FROM INVESTING ACTIVITIES:			
Additions to property and equipment		(228,000)	(340,000)
Purchase of long-term equity investments		(87,000)	(350,000)
Sale of marketable securities		1,000	1,374,000
Decrease in notes receivable			
Loan from officer			253,000
Payout of options to former officer			(45,000)
Change in permit acquisition cost		(67,000)	(13,000)
Net cash (used for) provided by investing activities		(381,000)	879,000

Three months ended June 30,

CASH FLOWS FROM FINANCING ACTIVITIES		
Net proceeds from borrowings	 10,000	49,000
CHANGE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of period	1,164,000 4,398,000	1,995,000 1,689,000
CASH AND CASH EQUIVALENTS, end of period	\$ 5,562,000	\$ 3,684,000

See notes to condensed consolidated financial statements.

6

SCHERER HEALTHCARE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1.

The accompanying unaudited condensed consolidated financial statements of Scherer Healthcare, Inc. and its subsidiaries (the "Company") include all adjustments that, in the opinion of management, are necessary for a fair presentation of the results for the period indicated. Quarterly results of operations are not necessarily indicative of annual results. These statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2001.

NOTE 2.

The components of inventory at June 30, 2001 and March 31, 2001 consisted of the following:

	June 30, 2001		March 31, 2001
Finished products	\$ 40,000) \$	65,000
Containers, packaging, and raw materials	263,000)	268,000
		_	
Total	\$ 303,000	\$	333,000

Inventories are stated at the lower of net realizable value or cost using the First-in, first-out ("FIFO") method.

NOTE 3.

Debt and obligations under capital leases at June 30, 2001 and March 31, 2001 consisted of the following:

	June 30, 2001		March 31, 20	
Obligations under capital leases, due in varying installments				
through fiscal 2006	\$	826,000	\$	816,000
Less current maturities		(271,000)		(265,000)
Long-term debt	\$	555,000	\$	551,000

NOTE 4.

The Company has the following investments as of June 30, 2001 and March 31, 2001:

	June 30, 2001		M	arch 31, 2001
Investments in marketable securities, at fair value	\$	7,794,000	\$	7,843,000
Equity method investments in unconsolidated companies,				
net		3,293,000		3,167,000
Other investments, at cost	270,000			270,000
Total	\$	11,357,000	\$	11,280,000

The Company's investments, at market value, consist of investments in long-term high-grade marketable securities composed primarily of government and corporate fixed income bonds. These marketable securities are classified as available-for-sale and are being carried at fair market value based on quoted market prices. The net unrealized holding gains (losses) on these investments are reported under capital in excess of par value as other comprehensive income (loss) and were (\$48,000) for the three months ended June 30, 2001, and the accumulated balance was (\$327,000) as of June 30, 2001.

7

The amortized cost and fair market value of the Company's marketable securities are as follows:

	 Amortized Cost	τ	Net Unrealized Loss		Fair Market Value
June 30, 2001					
Municipal bonds	\$ 6,609,000	\$	(211,000)	\$	6,398,000
Corporate bonds	1,214,000		(82,000)		1,132,000
Preferred stocks	298,000		(34,000)		264,000
	 			_	
Total	\$ 8,121,000	\$	(327,000)	\$	7,794,000
				_	
March 31, 2001					
Municipal bonds	\$ 6,608,000	\$	(148,000)	\$	6,460,000
Corporate bonds	1,215,000		(107,000)		1,108,000
Preferred stocks	299,000		(24,000)		275,000
	 0.100.000	Φ.	(2.50,000)	Φ.	7 0 4 2 000
Total	\$ 8,122,000	\$	(279,000)	\$	7,843,000

The net unrealized losses of the Company's marketable securities at June 30, 2001, and March 30, 2001, are detailed as follows:

June 30, 2001	Gross Gross Unrealized Unrealized Gains Losses		Net Unrealized Losses			
Municipal bonds	\$	20,000	\$	(231,000)	\$	(211,000)
Corporate bonds		1,000		(83,000)		(82,000)
Preferred stocks				(34,000)		(34,000)
Total	\$	21,000	\$	(348,000)	\$	(327,000)
March 30, 2001	Gross Unrealized Gains		Gross Unrealized Losses		Net Unrealized Losses	

Municipal bonds	\$ 21,000	\$	(169,000)	\$	(148,000)
Corporate bonds	1,000		(108,000)		(107,000)
Preferred stocks			(24,000)		(24,000)
		_		_	
Total	\$ 22,000	\$	(301,000)	\$	(279,000)

The amortized cost and estimated fair value of the securities (excluding the preferred stocks) at June 30, 2001, by contractual maturity, are shown below:

	 ortized Cost	F	Fair Market Value
Due in one year or less	\$	\$	
Due after one year through five years	454,000		466,000
Due after five years through ten years	211,000		208,000
Due after ten years	7,158,000		6,856,000
Total	\$ 7,823,000	\$	7,530,000

The Company had investments in unconsolidated companies, recorded on the equity method of accounting, of \$3,293,000 and \$3,167,000 as of June 30, 2001 and March 31, 2001, respectively. The Company's equity in net income of unconsolidated companies was \$39,000 for the first quarter of fiscal year 2002.

8

The equity method of accounting is used for companies and other investments in which the Company has significant influence. Generally this represents common stock ownership or convertible rights of at least 20% and not greater than 50%, and for investments in limited liability companies of at least 5% of ownership percentages. The Company has equity method investments in Compliance1, Inc., MedicareFacts, LLC, and Econometrics, Inc.

Compliance 1, Inc. manages the Health and Safety Information Service, a joint venture with the U.S. Department of Commerce, which facilitates agri-chemical and crop protection product compliance in cooperation with the U.S. Environmental Protection Agency and state departments of agriculture. Its internet-based solution consolidates the official up-to-date information needed by online market places to comply with federal, state, and local regulations. The Company's investment is in the form of three-year 10% secured convertible debentures in the aggregate principal amount of \$1,165,000, which mature on various dates during 2003, and which converts, at the Company's option, into 34.2% of the outstanding common stock of Compliance 1, Inc. as of June 30, 2001.

MedicareFacts, LLC designs and develops reimbursement guides which provide a single source for all coding and coverage information needed to file accurate Medicare claims, thus ensuring optimal reimbursement and compliance with government regulations. These products are used principally by hospitals and clinical laboratories. The Company's investment is in the form of a two-year 10% series B unsecured convertible note in the aggregate principal amount of \$400,000 that matures in October 2002, and which converts, at the Company's option, into 20% of the outstanding common stock of MedicareFacts, LLC as of June 30, 2001.

Econometrics, Inc. is a database marketing company that manages its own national consumer database of 180 million consumers and links marketers to its national database through the Internet. The Company's investment is in the form of a five-year 8% unsecured convertible debenture in the aggregate principal amount of \$2,000,000 that matures in October 2004, a three-year 10% unsecured convertible debenture for \$100,000, plus warrants to purchase common stock, that matures in June 2003, and two 18% unsecured promissory notes for the amounts of \$50,000 and \$87,000 that mature in December 2001. As of June 30 2001, the \$2,100,000 in debentures converts into 24.5% of the outstanding common stock of Econometrics, Inc.

The Company has an investment in Renaissance Pharmaceuticals, Inc. which is recorded at historical cost under the cost method. Renaissance Pharmaceuticals, Inc. is a development stage drug delivery company. The Company has a direct investment of \$650,000 in Renaissance Pharmaceuticals, Inc. for 2.5% of the outstanding common stock as of June 30, 2001. During the quarter ending December 31, 2000, the Company recorded an impairment charge of \$380,000 against its investment in Renaissance Pharmaceuticals, Inc. due to a revised valuation by the management of Renaissance Pharmaceuticals, Inc. in connection with Renaissance Pharmaceuticals, Inc.'s \$5.2 million convertible preferred

stock offering.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains, in addition to historical information, "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs. When used in this report, the words "may," "could," "should," "would," "believe," "anticipate," "estimate," "expect," "intend," "plan" and similar expressions are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. The Company cautions that various factors, including the factors described in the Company's filings with the Securities and Exchange Commission, as well as general economic conditions, changes in applicable laws and regulations, industry trends, a dependence upon and/or loss of key employees, vendors or customers, the loss of

9

strategic product shipping relationships, customer demand, product availability, competition (including pricing and availability), concentrations of credit risks, distribution efficiencies, capacity constraints and technological difficulties could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements of the Company. Reference is made to this report as well as the Company's most recent Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission for other factors that could affect the forward-looking statements. Any forward-looking statement speaks only as of the date of this report and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statements is made or to reflect the occurrence of an unanticipated event. New factors emerge from time to time, and it is not possible for the Company to predict all of such factors. Further, the Company cannot assess the impact of each such factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Results of Operations

Net Sales and Operating Income (Loss).

The following table sets forth, for the periods indicated, the net sales and operating income (loss) for each segment of the business of the Company and its subsidiaries:

	Three months ended June 30,			
	2001		2000	
NET SALES:				
Waste Management Services Segment	\$ 4,571,000	\$	4,204,000	
Consumer Healthcare Products Segment	463,000		422,000	
		_		
Company Totals	\$ 5,034,000	\$	4,626,000	
OPERATING INCOME (LOSS):				
Waste Management Services Segment	\$ 598,000	\$	585,000	
Consumer Healthcare Products Segment	178,000		167,000	
Corporate	(222,000)		(186,000)	
Company Totals	\$ 554,000	\$	566,000	

The Company's net sales increased 9% to \$5,034,000 for the first quarter of fiscal 2002 from \$4,626,000 for the first quarter of fiscal 2001. The Company's operating income decreased 2% to \$554,000 for the first quarter of fiscal 2002 from \$566,000 during the same period in fiscal 2001. The Company's cost of goods sold increased to 63% of net sales for the quarter ended June 30, 2001 from 60% of net sales for the quarter ended June 30, 2000. Selling, general, and administrative expenses decreased to 26% of net sales for the first quarter of fiscal 2002 from 28% for the first quarter of fiscal 2001. The primary reasons for these changes are discussed below.

The Company's cost of goods sold of the Waste Management Services Segment is made up of direct labor and related costs and benefits to collect and process waste, vehicle and equipment maintenance, repair and depreciation, waste disposal costs and interest on capital leases used to finance vehicle acquisitions. The cost of goods sold for the Consumer Healthcare Products Segment is made up of the cost of materials for products distributed and the related shipping expenses. Selling, general and administrative expenses in both of the Company's business segments is made up of:

management, administrative and office compensation, related costs and benefits, and

utilities, insurance, property depreciation, bad debt, professional fees, rent, amortization, advertising promotion, travel and miscellaneous other expenses.

10

The results of operations of the Company are dependent upon the results of operations of each of its subsidiaries operating in the Company's individual business segments. Set forth below is a discussion of the results of operations of each of these segments.

Waste Management Services Segment

Net sales in the Company's Waste Management Services Segment, which operates through Bio Systems Partners, Bio Waste Systems, Inc., and Medical Waste Systems, Inc. (collectively, "Bio Systems"), increased to \$4,571,000 for the first quarter of fiscal 2002 from \$4,204,000 for the first quarter of fiscal 2001. As in the past few years, the sales growth is primarily due to securing new hospital contracts for Bio Systems' core business of providing "sharps" (including sharp-edged medical waste such as scalpels, syringes, and needles) disposal services which utilize cost effective reusable containers.

Bio Systems' operating income increased 2% to \$598,000 for the quarter ended June 30, 2001 from \$585,000 for the quarter ended June 30, 2000. Bio Systems' cost of goods sold increased to 66% of net sales for the first quarter of fiscal 2002 from 62% of net sales for the first quarter of fiscal 2001. Selling, general, and administrative expenses decreased to 21% of net sales for the quarter ended June 30, 2001 from 24% of net sales during the same period in fiscal 2001.

Preparing new accounts for service requires, among other things, installation of Bio Systems' reusable containers and sometimes considerable operational follow-up which causes increases in certain costs and expenses such as operating payroll and expense for the hardware related to the installation of the reusable containers. The average cost of hardware per new installation is \$6,000 and the average payroll cost for a new installation is \$2,000. Although Bio Systems continues to increase revenue through new hospital contracts, the pricing pressures discussed above combined with certain contract restrictions have hampered Bio Systems' ability to effectively absorb these costs and expenses as compared to prior periods.

Additionally, Bio Systems' costs and expenses for waste disposal have increased slightly due to the outsourcing of the disposal of the laboratory and surgical fluid waste discussed above. Disposal costs increases amounted to \$164,000 more for the first quarter of fiscal year 2002 than was paid for the first quarter of fiscal 2001. Disposal costs were \$462,000 and \$298,000 for fiscal 2002 and 2001 respectively. The reusable containers that Bio Systems uses to collect the laboratory and surgical fluid waste are larger than the sharps collection containers and the waste disposal machinery at Bio Systems' processing facility is not currently equipped to process these larger containers. In future periods, Bio Systems intends to process these larger containers at its processing facility by retrofitting its waste disposal system at a cost that is not expected to be material to Bio Systems' results of operations. The cost to upgrade the Company's processing facility to handle the large containers is estimated to be \$500,000.

Consumer Healthcare Products Segment

Net sales for the Consumer Healthcare Products Segment, which operates through Scherer Laboratories, Inc. ("Scherer Labs"), increased 10% to \$463,000 for the first quarter of fiscal 2002 from \$422,000 during the same period in fiscal 2001. As in recent years, this increase is primarily due to new customers and increased volume of existing customers.

Scherer Labs' operating income increased 7% to \$178,000 for the first quarter of fiscal 2002 from \$167,000 for the first quarter of fiscal 2001. The gross profit generated from increased sales, increased operation income, and selling, general and administrative expenses did not materially change for the first quarter of fiscal 2002 from fiscal 2001.

Corporate

The Company's operating expenses in the Corporate Segment increased to \$222,000 for the quarter ended June 30, 2001 from \$186,000 for the quarter ended June 30, 2000. Certain administrative, accounting, management oversight and payroll services are performed by the Company's Corporate office. The Corporate operating expenses include the salaries and wages of the personnel who perform these functions (including the Company's executive officers) rent expense, and professional accounting and legal fees. The increase in the Corporate operating expenses is primarily due to the increase in accounting and consulting fees incurred during the first quarter of fiscal 2002.

Other Income.

The Company's interest income decreased to \$192,000 for the first quarter of fiscal 2002 from \$241,000 for the first quarter of fiscal 2001. The decrease is a result of the Company not accruing interest earned on one of its equity investments. During the first quarter of fiscal 2002, the Company recorded \$39,000 of equity in net income of unconsolidated companies.

Provision for Income Taxes

During fiscal 2001, the Company determined that it would, more likely than not, realize the benefit of its deferred tax assets and so it removed the remaining valuation allowance against the net amount of such assets. Therefore, the Company will recognize tax provision during fiscal year 2002 to the extent of its taxable income. During the first quarter of fiscal 2002, the Company's taxable income used the remaining net operating loss carryforward balance that existed as of March 31, 2001. The provision for income taxes increased \$253,000 to \$282,000 for the first quarter of fiscal 2002 from \$29,000 for the first quarter of fiscal 2001.

Liquidity and Capital Resources

The Company's cash and cash equivalents totaled \$5,562,000 at June 30, 2001, an increase of \$1,164,000 from March 31, 2001. Since March 31, 2001, the Company made an additional investment of \$87,000 in Econometrics, Inc.. The Company's working capital increased to \$7,762,000 at June 30, 2001 from \$7,096,000 at March 31, 2001. The increase was primarily for reasons described below.

Cash Flows from Operating Activities.

The Company's cash provided by operating activities from operations totaled \$1,535,000 for the first quarter of fiscal 2002, as compared to \$1,067,000 for the first quarter of fiscal 2001. The increase is primarily due to increased sales, reduction of accounts receivable and increased accounts payable and accrued expenses at June 30, 2001.

Cash Flows from Investing and Financing Activities.

The Company's investing activities used cash of \$381,000 during the quarter ended June 30, 2001, as compared to providing \$879,000 during the quarter ended June 30, 2000. In the first quarter of 2002, the Company increased its investment in equity investments by \$87,000 and increased property and equipment by \$228,000. See Note 4 of the accompanying Notes to Condensed Consolidated Financial Statements included elsewhere herein.

New capital lease obligations associated with the Waste Management Service Segment decreased the Company's cash from financing activities to \$10,000 for the first quarter of fiscal 2002 compared with \$49,000 during the first quarter of fiscal 2001.

Management of the Company believes that its current cash on hand and its current cash flow is sufficient to maintain its current operations. The Company continues to evaluate its long-term options

12

with regard to the use of its remaining cash on hand including possible investment and acquisition opportunities.

Effects of Accounting Standards

In June 2001, the Financial Accounting Standards Board (FASB) issued Statement No. 141, "Business Combinations," which established new accounting and reporting standards for business combinations and supersedes Accounting Principles Board (APB) Opinion No. 16. All business combinations initiated after June 30, 2001, must now be accounted for using the purchase method of accounting.

Also in June 2001, the FASB issued Statement No. 142, "Goodwill and Other Intangible Assets," which establishes new accounting and reporting standards for acquired goodwill and other intangible assets and supersedes APB Opinion No. 17. It addresses how intangible assets that are acquired individually or with a group of other assets (but not those acquired in a business combination) should be accounted for upon acquisition and on an ongoing basis. Goodwill and intangible assets that have indefinite useful lives will not be amortized but rather will be tested at least annually for impairment. Intangible assets that have finite useful lives will continue to be amortized over their useful lives, which are no longer limited to 40 years. The provisions of Statement No. 142 must be adopted on April 1, 2002, by the Company. The Company recorded amortization expense related to goodwill of \$27,000 for the three months ended June 30, 2001, and is expected to record \$107,000 of goodwill amortization expense for the year ending March 31, 2002. The Company has not yet quantified the impact of adopting Statement No. 142 on its consolidated financial statements; however, the impact is not expected to be material upon adoption on April 1, 2002.

PART II. OTHER INFORMATION

Item 6. Exhibits	and Reports on Form 8-K			
(a)	Exhibits None			
(b)	Reports on Form 8-K.			
	None.			
		13		

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SCHERER HEALTHCARE, INC. (Registrant)
Date:	/s/ ROBERT P. SCHERER, JR.
	Robert P. Scherer, Jr. Chairman, Chief Executive Officer and President
Date:	/s/ DONALD P. ZIMA
	Donald P. Zima Vice President and Chief Financial Officer 14

QuickLinks

SCHERER HEALTHCARE, INC.

Quarterly Report on Form 10-Q For the Quarter Ended June 30, 2001

Table of Contents

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS' EQUITY

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

SCHERER HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

SCHERER HEALTHCARE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SIGNATURES